HCK and mantle cell lymphoma: Taken together, our results show that the dual HCK/BTK inhibitor KIN-8194 potently inhibits the growth and integrin-mediated adhesion of MCL cells, independent of their sensitivity to BTKi, at in vivo relevant concentrations.